Table 55Results from fixed-effects Bayesian MTC Sub-Group Analysis for Major Bleeding Compared with Adjusted-Dose Warfarin by TTR

WarfarinTreatmentWarfarin
Event
Rate
ARR Per 1,000
Patients Treated
Each Year,
Study-Level
Bayesian
MTC, Median
OR (95% CrI)
NNNN
TTR < 66%
Apixaban 5 mg b.i.d.2174,5301254,5174.8%11 fewer
(8 fewer, 14 fewer)
0.57 (0.46 to 0.71)
Dabigatran 110 mg b.i.d.2253,0181713,0217.5%9 fewer
(3 fewer, 14 fewer)
0.75 (0.61 to 0.92)
Dabigatran 150 mg b.i.d.2253,0181763,0357.5%9 fewer
(2 fewer, 14 fewer)
0.77 (0.63 to 0.94)
Rivaroxaban 20 mg q.d.2715,2842495,2527.5%2 fewer
(3 more, 6 fewer)
0.92 (0.78 to 1.10)
TTR ≥ 66%
Apixaban 5 mg b.i.d.2454,5172014,5225.4%6 fewer
(0 more, 10 fewer)
0.82 (0.67 to 0.99)
Dabigatran 110 mg b.i.d.19429961662,9566.5%4 fewer
(2 more, 10 fewer)
0.86 (0.70 to 1.07)
Dabigatran 150 mg b.i.d.1942,9962212,9986.5%5 more
(13 more, 2 fewer)
1.15 (0.95 to 1.41)
Rivaroxaban 20 mg q.d.1151,8391351,6896.3%11 more
(25 more, 0 more)
1.30 (1.01 to 1.69)

ARR= absolute risk reduction; CrI = credible interval; MTC = mixed treatment comparison; OR = odds ratio; TTR = time in therapeutic range.

From: 7.12, Specific Outcome Results

Cover of Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet].
Wells G, Coyle D, Cameron C, et al.
Copyright © 2012 Canadian Collaborative for Drug Safety, Effectiveness and Network Meta-Analysis.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.